Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Kazia Therapeutics Ltd (KZIA)

10.56   0.04 (0.38%) 06-18 08:42
Open: 10.42 Pre. Close: 10.52
High: 10.96 Low: 10.3001
Volume: 30,051 Market Cap: 137M

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 10.972 - 11.016 11.016 - 11.053
Low: 10.184 - 10.236 10.236 - 10.28
Close: 10.47 - 10.555 10.555 - 10.628

Technical analysis

as of: 2021-06-17 4:44:59 PM
Stoxline posted a NEUTRAL today, upgraded from lower rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 13.95     One year: 16.29
Support: Support1: 10.12    Support2: 9.00
Resistance: Resistance1: 11.94    Resistance2: 13.95
Pivot: 10.14
Moving Average: MA(5): 10.56     MA(20): 9.90
MA(100): 10.63     MA(250): 8.44
MACD: MACD(12,26): 0.11     Signal(9): -0.02
Stochastic oscillator: %K(14,3): 53.57     %D(3): 53.72
RSI: RSI(14): 58.74
52-week: High: 15.85  Low: 3.12  Change(%): 222.9
Average Vol(K): 3-Month: 8695  10-Days: 7548

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
KZIA has closed below upper band by 23.6%. Bollinger Bands are 35% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Thu, 17 Jun 2021
Kazia Therapeutics Limited - ADR (KZIA) gains 0.3800% for June 17 -

Tue, 15 Jun 2021
Kazia enters clinical collaboration with Cornell University for mid-stage glioblastoma trial - Seeking Alpha

Tue, 15 Jun 2021
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma - PRNewswire

Mon, 14 Jun 2021
Kazia Therapeutics Limited - ADR (KZIA) gains 0.4780% for June 14 -

Thu, 10 Jun 2021
Kazia Therapeutics Limited - ADR (KZIA) gains 2.7810% for June 10 -

Mon, 07 Jun 2021
Study of Paxalisib in Primary CNS Lymphoma at Dana-Farber Cancer Institute Enrols First Patient - PRNewswire

Financial Analysis

Growth n/a
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability n/a
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency n/a
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency n/a
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Neutral Discounted cash flow: Neutral
Return on Assets: Neutral Price to Earnings: Neutral
Return on Equity: Neutral Debt to Equity: Neutral
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 13
Shares Float (M) 9
% Held by Insiders
% Held by Institutions 4.21
Shares Short (K) 41
Shares Short P. Month (K) 28

Stock Financials

EPS -1.060
EPS Est This Year
EPS Est Next Year
Book Value (p.s.) 2.510
Profit Margin
Operating Margin -3563.68
Return on Assets (ttm) -26.9
Return on Equity (ttm) -59.0
Qtrly Rev. Growth -99.8
Gross Profit (p.s.) 0.078
Sales Per Share 0.029
EBITDA (p.s.) -0.938
Qtrly Earnings Growth
Operating Cash Flow (M) -18
Levered Free Cash Flow (M) -7

Stock Valuations

PE Ratio -9.96
PEG Ratio
Price to Book value 4.21
Price to Sales 367.79
Price to Cash Flow -7.29

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date 2017-07-13
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.